Press Releases

Press Releases

Date	Title	View
November 14, 2024	AN2 Therapeutics to Participate at Upcoming Investor Conferences
November 13, 2024	AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
October 17, 2024	AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
August 28, 2024	AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 16, 2024	AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
August 13, 2024	AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
August 8, 2024	AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
May 14, 2024	AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
March 28, 2024	AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
February 12, 2024	AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Investors